NCT03693339View on ClinicalTrials.gov

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

PHASE2UnknownINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2022

Conditions
CancerLung Cancer MetastaticMET Gene Mutation
Interventions
DRUG

Capmatinib

Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT03693339 - Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation | Biotech Hunter | Biotech Hunter